Bloomsbury Genetic Therapies launches with $5.5 Million in Seed Financing

Bloomsbury Genetic Therapies, which is developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases, launched with $5.5 million (£5 million) in seed financing.

Photo: Adrien Lemoine, co-founder and CEO of Bloomsbury

UCL Technology Fund led the financing.

Bloomsbury was founded as a spinout from UCL, and was supported by UCL Business, which helped foster the progression of these translational projects, supporting the team while managing the intellectual property, and making this deal possible.

The company has programs in ornithine transcarboxylase deficiency (OTCD), dopamine transporter deficiency syndrome (DTDS), Niemann-Pick Disease Type C (NPC), and infantile neuroaxonal dystrophy (INAD).

The company said the programs have been designed with well-characterized adeno-associated virus capsids that have demonstrated success in clinical or commercial settings. They have also been combined with innovative cassettes and routes of administration designed for optimal therapeutic effect.

“Bloomsbury is developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases,” said Adrien Lemoine, co-founder and CEO of Bloomsbury. “Our approach has been designed with a single goal in mind—to deliver the promise of gene therapy to rare disease patients by leveraging our industry’s existing state-of-the art technology.”

Author: Rare Daily Staff